With a steadfast commitment to innovation and excellence, Just – Evotec Biologics is pioneering a new era in biologics manufacturing. Transitioning to our intensified continuous production before manufacturing at commercial scale can drive value creation in a late-stage manufacturing process.

For early-stage and first-in-human (FIH) clinical trials, the platform can operate a 15-day single bioreactor process to produce sufficient material. The same equipment can be scaled up for commercial biomanufacturing by running up to 6 bioreactors for 25-40 days, enabling flexible production from less than 10 kg to over 2,000 kg annually.

Learn more about how the platform reduces risk, our recommendations for transitioning to commercial production and typical timelines from cell line transfer to BLA-enabling studies for developing a continuous process for commercial manufacturing by registering to download our whitepaper.